Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Author(s) -
H. Borghaei,
L. Paz-Ares,
Leora Horn,
David R. Spigel,
Martin Steins,
Neal Ready,
Laura Q.M. Chow,
Everett E. Vokes,
Enriqueta Felip,
Esther Holgado,
Fabrice Barlési,
M. Kohlhufl,
Óscar Arrieta,
M. Burgio,
Jérôme Fayette,
H. Lena,
Elena Poddubskaya,
David E. Gerber,
Scott Gettinger,
Charles M. Rudin,
Naiyer A. Rizvi,
L. Crina,
George R. Blumenschein,
Scott Antonia,
Cécile Dorange,
Christopher Harbison,
F. Graf Finckenstein,
Julie R. Brahmer
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1507643
Subject(s) - medicine , docetaxel , nivolumab , lung cancer , oncology , cancer , immunotherapy
Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom